Akif Selim Yavuz, MD

adkfor@r.postjobfree.com www.linkedin.com/in/akif-selim-yavuz +1-305-***-****

**** ** ** ******, ***** FL 33178

GOALS:

Utilizing my vast knowledge as an experienced physician in internal medicine and hematology coupled with clinical Phase 2,3,4 studies in drug development and clinical research in an innovative organization.

Having recently moved to over to the US from Sweden as a lawful permanent resident, seeking to lead clinical research studies in a pharmaceutical or in a medical school environment. Flexible to relocate if required.

KEY ACCOMPLISHMENTS:

Drug Development:

Experience with clinical phase 2,3 and 4 studies of drug development in systemic mastocytosis, chronic myeloid leukemia, primary myelofibrosis

Ad hoc member of a number of Scientific Advisory Boards for several pharmaceutical companies in the fields of TKI treatment of CML and systemic mastocytosis

Experienced physician:

Experienced physician with more than 30 years of clinical practice in Internal Medicine and Hematology and a thought leader for systemic mastocytosis and myeloproliferative neoplasms

oMember of the European Competence Network of Mastocytosis (ECNM) and organizer of the Annual ECNM Meeting 2011 in Istanbul, Turkey

oCo-author of several papers of the ECNM group on systemic mastocytosis including recommendations for diagnosis and treatment

oExpert on molecular and clinical monitorization of patients with chronic myeloid leukemia using tyrosine kinase inhibitors

ECFMG certificate in 1999

Research:

Focused on translational and clinical research in hematology

oDelineating the evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis using single cell analysis of the mutations in the c-kit gene

oPhase 2 study of midostaurin in advanced systemic mastocytosis

oFrontline nilotinib in Turkish chronic myeloid leukemia patients

oInfluence of hypermutational machinery of B cells in the germinal centers to the mutations of different genes as candidates for lymphomagenesis (see publications)

oJAK2 and other myeloid mutations in myeloproliferative neoplasms

oTrack record of accomplishment in publishing exemplified by more than 1150 citations

Successful international collaborations (Uppsala University, ECNM)

Active member of European Competence Network of Mastocytosis

PI or co-PI of collaborative studies with pharmaceutical companies (Phase 2,3,4): Midostaurin in advanced systemic mastocytosis (NCT00233454, Phase 2), nilotinib in CML patients (CAMN107A2109, Phase 4), frontline nilotinib in Turkish CML patients (NCT01274351, Phase 2), ABL001(asciminib) vs bosutinib in CML (NCT03106779, Phase 3)

Profile

Enthusiastic at work and eager to learn new developments

Skilled in therapeutics, trial design, outcome measure, biostatistics, translational research, medical writing, and public speaking

Specialties: problem-solving, decision making, strong leadership

Adherent to SOPs in Clinical Research and Development

PROFESSIONAL EXPERIENCE

Uppsala University, Uppsala

Guest Researcher, Department of Medical Sciences, Division of Hematology Uppsala, Sweden, 2019-2020

Focused on systemic mastocytosis and blood stem cell transplantation donors

Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology

Professor, 2009-2018, Associate Professor 2003-2009, Specialist in Hematology 2005, Specialist in Internal Medicine 1992-2005, resident 1987-1992, Istanbul, Turkey

Head of Molecular Hematology Lab

Patient care in a hematology ward consisting of 50 beds and a busy outpatient clinic taking care of the largest systemic mastocytosis and MPN cohorts in Turkey

Responsible for medical students, resident, and fellowship training programs for internal medicine and hematology

PI of several clinical trials in the field of systemic mastocytosis, CML and MPNs

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Bethesda

Post-doc Fellow 1999-2000 and contractor 2000-2005 (intermittently), Autoimmunity Branch. NIAMS National Institutes of Health (NIH), Bethesda, USA,

Participated in several research projects on the effects of somatic hypermutational machinery of human B cells to non-Ig genes and clonality of systemic mastocytosis using single cell analysis

University of Texas Southwestern Medical Center at Dallas

Fellow, Rheumatic Diseases Division, UT Southwestern Medical Center,

Harold C. Simmons Arthritis Research Center, Dallas, USA, 1998-1999

Conducted research on somatic hypermutational mechanisms of germinal centers using single cell DNA amplification and sequencing

Various Hospitals in Switzerland (Kantonsspital Uri, Regionalspital Interlaken, Bruderholzspital in Basel)

Internships during medical education, 1978-1983

EDUCATION

Certified in Hematology

Istanbul University, Istanbul Faculty of Medicine, Division of Hematology – Istanbul, Turkey-2005

Certified in Internal Medicine

Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine – Istanbul, Turkey-1992

Doctor of Medicine Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey-1983

Sankt Georg Austrian High School (“Matura” in German), Istanbul, Turkey 1969-1977

CERTIFICATION

Good Clinical Practice (GCP)

ECFMG 1999

SKILLS:

Technology: Microsoft Office applications including Word, Excel, PowerPoint, SPSS

Languages: Turkish-native, English-fluent, German-fluent, Swedish (C1 level), Latin

Interests: Tennis, skiing, travelling, trekking, culinary activities

PUBLICATIONS

Author or co-author of publications in peer reviewed prestigious

journals with over 1150 citations.

VISA STATUS IN US

Lawful permanent resident

SELECTED PUBLICATIONS

1. Yavuz S, Grammer AC, Yavuz AS, et al. Comparative characteristics of mu and alpha chains transcripts expressed by individual tonsil plasma cells. Mol Immunol 2001; 38: 19-34.

2. Yavuz AS, Lipsky PE, Yavuz S, et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002; 100: 661-665.

3. Yavuz AS, Monson NL, Yavuz S, et al. Different patterns of bcl-6 and p53 mutations in tonsillar B cells indicate seperate mutational mechanisms. Mol Immunol 2002; 39:485-493.

4. Yavuz S, Yavuz AS, Kraemer KH, Lipsky PE. The role of polymerase in somatic hypermutation determined by analysis of mutations in a patient with xeroderma pigmentosum variant. J Immunol 2002; 169:3825-3830.

5. Yenerel MN, Atamer T, Yavuz AS, et al. Myeloid antigen expression provides favorable outcome in patients with adult acute lymphoblastic leukemia: a single-center study. Ann Hematol 2002; 81:498-503.

6. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103:3222-3225.

7. Kocabas CN, Yavuz AS, Lipsky PE, Metcalfe DD, Akin C. Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature. J Allergy Clin Immunol 2005; 115:1155-61.

8. Hancer VS, Kose M, Diz-Kucukkaya R, Yavuz AS, Aktan M. Activation-induced cytidine deaminase mRNA levels in chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Jan;52(1):79-84

9. Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-

Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P, Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis, Biology of Blood and Marrow Transplantation (2016), doi: 10.1016/j.bbmt.2016.04.018.

10. Sperr WR, Kundi M, Alvarez-Twose I, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019;6(12):e638-e649. doi:10.1016/S2352-3026(19)30166-8

11. Kluin-Nelemans HC, Reiter A, Illerhaus A, et al. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia. 2020;34(4):1090-1101. doi:10.1038/s41375-019-0632-4

12. Daglar-Aday A, Akadam-Teker B, Yonal-Hindilerden I, Dermenci H, Sahin E, Hindilerden F, Yilmaz-Aydogan H, Ozturk O, Yavuz AS. The impact of CYP2D6*4 and GSTP1 Ile105Val polymorphisms on the susceptibility to develop BCR-ABL1 negative myeloproliferative neoplasms. Mol Biol Rep. 2020 Sep 11. doi: 10.1007/s11033-020-05796-7. Epub ahead of print. PMID: 32918123.

Contact this candidate